Catalyst Wire Dossier Catalyst Wire Dossier

Rilvegostomig

rilvegostomig
Drug timelines are a Plus or Pro feature.

16 regulatory and trial events tracked for Rilvegostomig, covering 2024-08-26 to 2026-04-24. Get the full timeline:

Most recent: Clinical Trial Update: A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer [Phase 3]

See pricing